Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_assertion type Assertion NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_head.
- NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_assertion description "[JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_provenance.
- NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_assertion evidence source_evidence_literature NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_provenance.
- NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_assertion SIO_000772 25189729 NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_provenance.
- NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_assertion wasDerivedFrom befree-2016 NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_provenance.
- NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_assertion wasGeneratedBy ECO_0000203 NP1217010.RAZTJsroeLIEm_5rBIqN2jQHHKfyx24PTG9it9VMJhCn4130_provenance.